Vertex's Journavx got FDA approval for acute pain but faces adoption challenges. Click here to read more about VRTX stock and ...

On Wednesday, the U.S. Food and Drug Administration approved a new pain management drug which could change the way healthcare ...

Journavx, a new non-opioid pain medication, offers a safer alternative for managing acute pain while reducing the risk of ...

Introducing Journavx: the FDA-approved non-opioid, non-addictive drug for acute pain. A major breakthrough in pain medication ...

SALT LAKE CITY, UTAH / ACCESS Newswire / February 6, 2025 /CenExel, a leading network of clinical research sites, proudly ...

Now a third option is available after the U.S. Food and Drug Administration last week approved Vertex Pharmaceuticals’ Suzetrigine, sold as twice-daily Journavx, a non-addictive prescription drug for ...

The FDA recently approved Vertex Pharmaceuticals Incorporated’s Journavx (suzetrigine), a first-in-class non-opioid ...

For the first time in more than 25 years, the U.S. Food and Drug Administration has signed off on a new type of pain reliever ...

Kewalramani cast the moment as an “opportunity to change the paradigm of acute pain management and establish a new standard of care.” Still, Journavx faces some hurdles in winning over ...

The FDA has approved a new non-opioid prescription medication, Journavx for adults with moderate to severe acute pain.

FDA Approves Non-Opioid Treatment for Moderate to Severe Acute Pain as Agency Continues to Take Steps to Support New ...

A new opioid-free pain medication was approved by the FDA on Thursday, marking a non-addictive alternative for patients.